Systematic Financial Management LP Buys 41,363 Shares of InMode Ltd. $INMD

Systematic Financial Management LP lifted its position in InMode Ltd. (NASDAQ:INMD) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,090,971 shares of the healthcare company’s stock after buying an additional 41,363 shares during the quarter. Systematic Financial Management LP owned about 1.73% of InMode worth $15,754,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Parallel Advisors LLC lifted its stake in InMode by 63.1% in the second quarter. Parallel Advisors LLC now owns 1,973 shares of the healthcare company’s stock valued at $28,000 after acquiring an additional 763 shares during the last quarter. Summit Securities Group LLC bought a new stake in shares of InMode in the 1st quarter valued at about $70,000. Farther Finance Advisors LLC lifted its stake in InMode by 302.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 8,110 shares of the healthcare company’s stock valued at $117,000 after purchasing an additional 6,094 shares during the last quarter. Ritholtz Wealth Management acquired a new stake in InMode in the 2nd quarter valued at about $151,000. Finally, XTX Topco Ltd bought a new position in InMode during the first quarter worth about $182,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

INMD has been the topic of several research analyst reports. Zacks Research upgraded InMode from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Wall Street Zen lowered InMode from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Friday, October 10th. Canaccord Genuity Group lifted their price objective on shares of InMode from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Friday, October 10th. Finally, UBS Group decreased their price objective on shares of InMode from $16.25 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $16.80.

InMode Trading Down 0.4%

NASDAQ:INMD opened at $14.24 on Wednesday. The stock has a 50 day simple moving average of $14.82 and a 200 day simple moving average of $14.58. The stock has a market cap of $900.11 million, a P/E ratio of 6.59 and a beta of 2.14. InMode Ltd. has a 1-year low of $13.14 and a 1-year high of $19.78.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.